A Phase 3 clinical trial, PACIFIC, assessing AstraZeneca’s (NYSE:AZN) Imfinzi (durvalumab) in patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose cancer has not progressed following platinum-chemo concurrent with radiation therapy met the second of two primary endpoints.
An interim analysis by the independent Data Monitoring Committee showed that treatment with Imfinzi resulted in a statistically significant improvement in overall survival (OS) compared to placebo. The results will be submitted for presentation at an upcoming medical conference.
In May 2017, the company announced that the study met the first primary endpoint, demonstrating a statistically valid improvement in median progression-free survival (PFS) compared to control.
Imfinzi is approved in the U.S. and Canada for the indication. Marketing applications are currently under review in Europe, Japan and certain other countries.